Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	Jul 15	Data from 1960-1976 added to RDISCLOSURE
NEWS	5	Jul 21	Identification of STN records implemented
NEWS	6	Jul 21	Polymer class term count added to REGISTRY
NEWS	7	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	8	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	9	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	10	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	11	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	12	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	13	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	14	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	15	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	16	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	17	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	18	SEP 22	DIPPR file reloaded
NEWS	19	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	20	SEP 29	DISSABS now available on STN

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:59:36 ON 02 OCT 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 12:00:29 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2003 HIGHEST RN 596788-60-2
DICTIONARY FILE UPDATES: 1 OCT 2003 HIGHEST RN 596788-60-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading C:\Program Files\Stnexp\Queries\09740391.str





C:1

N:2

16 1:1

18 1:2

chain nodes :
9 10 11 12 13 14 15 17 22
ring nodes :
1 2 3 4 5 6 7 8
ring/chain nodes :
16 18
chain bonds :
3-9 7-12 8-10 9-10 9-11 12-13 12-14 14-22 15-16 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 5-6 7-12 7-8 9-11 14-22 15-16 17-18
exact bonds :
8-10 9-10 12-13 12-14

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
22:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:05:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5260 TO ITERATE

19.0% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

09/740,391 Thomas McKenzie

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 100853 TO 109547
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:05:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 104040 TO ITERATE

100.0% PROCESSED 104040 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.06

L3 33 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 152.95 153.37

FILE 'CAOLD' ENTERED AT 12:08:11 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3
L4 0 L3

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.40 153.77

FILE 'CAPLUS' ENTERED AT 12:08:55 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 2 Oct 2003 VOL 139 ISS 14
FILE LAST UPDATED: 1 Oct 2003 (20031001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L5          23 L3

=> s wo220032868?/pn
L6           0 WO220032868?/PN
                (WO2200032868/PN)

=> s wo20002032868?/pn
L7           0 WO20002032868?/PN

=> s wo-2002032868?/pn
L8           1 WO-2002032868?/PN
                (WO2002032868/PN)

=> s l5 not l8
L9          22 L5 NOT L8

=> sort py l9
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L9
L10         22 SORT L9 PY

=> file chemcat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                8.92     162.69

FILE 'CHEMCATS' ENTERED AT 12:14:24 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE LAST UPDATED 27 SEPTEMBER 2003 (20030927UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow
prompt. For the list of suppliers currently in the file, enter
HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ.
For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP
CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the
suppliers for current information regarding pricing, regional
availability, available quantities, purities, etc. THERE ARE NO
WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not
liable for any loss of profit, goodwill or any other damages arising
out of the use of this database.
```

CHEMCATS now contains more than 6 million records. See HELP CONTENT and NEWS FILE for details.

=> s l3
L11 0 L3

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.82	163.51

FILE 'CAPLUS' ENTERED AT 12:14:41 ON 02 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Oct 2003 VOL 139 ISS 14
FILE LAST UPDATED: 1 Oct 2003 (20031001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l10 cbib pi hitstr 1-22

L10 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1994:270133 Document No. 120:270133 Preparation of carbostyril derivatives as blood platelet aggregation inhibitors.. Sato, Seiji; Yukawa, Hirotaka; Kihara, Yoshito; Koga, Nobuyuki; Saito, Mashiro; Nishi, Takao (Otsuka Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9304042 A1 19930304, 218 pp. DESIGNATED STATES: W: AU, CA, KR, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE. (Japanese). CODEN: PIXXD2.
APPLICATION: WO 1992-JP1041 19920818. PRIORITY: JP 1991-211268 19910823.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9304042	A1	19930304	WO 1992-JP1041	19920818
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	CA 2093633	AA	19930224	CA 1992-2093633	19920818
	AU 9224292	A1	19930316	AU 1992-24292	19920818
	AU 653060	B2	19940915		
	EP 569592	A1	19931118	EP 1992-917806	19920818
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 05194405	A2	19930803	JP 1992-221206	19920820
	US 5506239	A	19960409	US 1993-39301	19930422
	US 5658926	A	19970819	US 1995-541579	19951010

IT **151641-21-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)
RN 151641-21-3 CAPLUS
CN Piperidine, 1-[[1-[4-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]butyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1995:731510 Document No. 123:144639 Preparation of peptide analog inhibitors of farnesyl protein transferase.. Patel, Dinesh V.; Kline, Toni B.; Meyers, Chester A.; Leftheris, Katerina; Bhide, Rajeev S. (Bristol-Myers Squibb Co., USA). Eur. Pat. Appl. EP 618221 A2 19941005, 110 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1994-302255 19940329. PRIORITY: US 1993-42377 19930402; US 1993-85338 19930629.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 618221	A2	19941005	EP 1994-302255	19940329
EP 618221	A3	19950215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2118985	AA	19941003	CA 1994-2118985	19940314
IL 108999	A1	19990714	IL 1994-108999	19940316
ZA 9401902	A	19941014	ZA 1994-1902	19940317
NO 9401181	A	19941003	NO 1994-1181	19940330
FI 9401519	A	19941003	FI 1994-1519	19940331
AU 9459184	A1	19941006	AU 1994-59184	19940331
AU 679716	B2	19970710		
CN 1098408	A	19950208	CN 1994-103570	19940331
HU 68080	A2	19950529	HU 1994-946	19940331
JP 07089935	A2	19950404	JP 1994-65933	19940404

IT **166169-69-3P 166169-71-7P 166170-22-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptide analog inhibitors of farnesyl protein transferase)
RN 166169-69-3 CAPLUS
CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(triphenylmethyl)thio]propyl]-L-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166169-71-7 CAPLUS
CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(triphenylmethyl)thio]propyl]-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166170-22-5 CAPLUS
CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(triphenylmethyl)thio]propyl]-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1995:921904 Document No. 123:339733 Preparation of indole derivatives for treatment of osteoporosis. Machii, Daisuke; Takai, Haruki; Kosaka, Nobuo; Seo, Hisakatsu; Sugiyama, Tomomi; Nakamura, Joji; Ishida, Hiroyuki; Gomi, Katsushige; Sato, Soichiro; Uchii, Masako (Japan). PCT Int. Appl. WO 9519343 A1 19950720, 48 pp. DESIGNATED STATES: W: AU, CA, CN, FI, HU, JP, KR, NO, NZ, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1995-JP19 19950111. PRIORITY: JP 1994-3334 19940118.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9519343	A1	19950720	WO 1995-JP19	19950111
W: AU, CA, CN, FI, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2181374	AA	19950720	CA 1995-2181374	19950111
AU 9514247	A1	19950801	AU 1995-14247	19950111
EP 741132	A1	19961106	EP 1995-905756	19950111
EP 741132	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 215932	E	20020415	AT 1995-905756	19950111
US 5891902	A	19990406	US 1996-676177	19960715

IT **170365-22-7P 170365-34-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. for treatment of osteoporosis)
RN 170365-22-7 CAPLUS
CN Piperidine, 1-[[3-[bis[4-(methoxymethoxy)phenyl]methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 170365-34-1 CAPLUS
CN Piperidine, 1-[[3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 170365-33-0
CMF C31 H35 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



L10 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1995:881293 Document No. 123:286080 Preparation of α-(mercaptoalkyl)-1-piperazineethanamines as inhibitors of farnesyl-protein transferase. Graham, Samuel L.; Williams, Theresa M. (Merck and Co., Inc., USA). PCT Int. Appl. WO 9500497 A1 19950105, 156 pp. DESIGNATED STATES: W: AU, BB,

BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1994-US5634 19940519. PRIORITY: US 1993-80028 19930618; US 1994-237586 19940511.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9500497	A1	19950105	WO 1994-US5634	19940519
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2165176	AA	19950105	CA 1994-2165176	19940519
	AU 9470412	A1	19950117	AU 1994-70412	19940519
	AU 675145	B2	19970123		
	EP 703905	A1	19960403	EP 1994-919174	19940519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09500109	T2	19970107	JP 1994-502810	19940519
	ZA 9404326	A	19951214	ZA 1994-4326	19940617
	US 5736539	A	19980407	US 1995-549829	19951116

IT **169448-91-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of α-(mercaptoalkyl)-1-piperazineethanamines farnesyl-protein transferase inhibitors)

RN 169448-91-3 CAPLUS

CN Carbamic acid, [1-[[4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-1-piperazinyl]methyl]-2-[(triphenylmethyl)thio]ethyl]-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1996:248963 Document No. 125:11480 Cyclopropapyrroloindole-oligopeptide anticancer agents. Lown, J. William; Wang, Yuqiang; Luo, Weide (Synphar Laboratories, Inc., Can.). U.S. US 5502068 A 19960326, 17 pp. (English). CODEN: USXXAM. APPLICATION: US 1995-381355 19950131.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5502068	A	19960326	US 1995-381355	19950131
	CA 2210093	AA	19960808	CA 1996-2210093	19960131
	WO 9623497	A1	19960808	WO 1996-US727	19960131
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,				

LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

AU 9649643	A1	19960821	AU 1996-49643	19960131
AU 698001	B2	19981022		
EP 800390	A1	19971015	EP 1996-906176	19960131
EP 800390	B1	20021204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11500427	T2	19990112	JP 1996-523576	19960131
AT 228837	E	20021215	AT 1996-906176	19960131

IT **177177-63-8P 177177-65-0P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(cyclopropapyrroloindole-oligopeptide anticancer agents)

RN 177177-63-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-(methoxymethyl)-N-[1-(methoxymethyl)-5-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-pyrrol-3-yl]-4-[(1-oxobutyl)amino]- (9CI) (CA INDEX NAME)



RN 177177-65-0 CAPLUS
CN 1H-Imidazole-2-carboxamide, 1-(methoxymethyl)-N-[1-(methoxymethyl)-2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-imidazol-4-yl]-4-[(1-oxobutyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1997:805736 Document No. 128:61425 Preparation of indolecarboxamidines and analogs as thrombin inhibitors. Koo, Bon Am; Min, Jae Ki; Hong, Woo Sang; Ryu, Eun Jung; Nam, Woong Hyun; Kim, Jong Min (C & C Research Laboratories, S. Korea; Koo, Bon Am; Min, Jae Ki; Hong, Woo Sang; Ryu, Eun Jung; Nam, Woong Hyun; Kim, Jong Min). PCT Int. Appl. WO 9745424 A1 19971204, 257 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-KR100 19970531. PRIORITY: KR 1996-19282 19960531.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745424	A1	19971204	WO 1997-KR100	19970531
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9730494	A1	19980105	AU 1997-30494	19970531
	EP 918768	A1	19990602	EP 1997-925316	19970531
	EP 918768	B2	20020109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1219932	A	19990616	CN 1997-195005	19970531
	CN 1079396	B	20020220		
	JP 2000504030	T2	20000404	JP 1997-542065	19970531
	JP 3202994	B2	20010827		
	AT 211741	E	20020115	AT 1997-925316	19970531
	ES 2171945	T3	20020916	ES 1997-925316	19970531
	CA 2256438	C	20021015	CA 1997-2256438	19970531
	US 6201006	B1	20010313	US 1998-180675	19981113

IT **200183-02-4P 200183-27-3P 200183-66-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolecarboxamidines and analogs as thrombin inhibitors)
RN 200183-02-4 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-

2-yl]ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200183-27-3 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2α(S*),4α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200183-66-0 CAPLUS
CN 1-Piperidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **200184-59-4P 200184-94-7P 200185-33-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolecarboxamidines and analogs as thrombin inhibitors)
RN 200184-59-4 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200184-94-7 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2α(S*),4α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200185-33-7 CAPLUS
CN 1-Piperidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1997:195777 Document No. 126:185982 Preparation of indole derivatives for the treatment of osteoporosis. Machii, Daisuke; Takai, Haruki; Suzuki, Koji; Kosaka, Nobuo; Sato, Soichiro (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 9703965 A1 19970206, 106 pp. DESIGNATED STATES: W: AU, CA, CN, HU, JP, KR, NO, NZ; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1996-JP1980 19960716. PRIORITY: JP 1995-181951 19950718.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703965	A1	19970206	WO 1996-JP1980	19960716
	W: AU, CA, CN, HU, JP, KR, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5891902	A	19990406	US 1996-676177	19960715
	CA 2199978	AA	19970206	CA 1996-2199978	19960716
	AU 9663701	A1	19970218	AU 1996-63701	19960716
	EP 782989	A1	19970709	EP 1996-923101	19960716
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

IT **187533-77-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. for the treatment of osteoporosis)

RN 187533-77-3 CAPLUS
CN Piperidine, 1-[[1-[2-(dimethylamino)ethyl]-3-(diphenylmethyl)-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1998:220858 Document No. 128:270614 Preparation of acylpiperazines and related compounds as inhibitors of farnesyl-protein transferase.. Graham, Samuel L.; Williams, Theresa M. (Merck and Co., Inc., USA). U.S. US 5736539 A 19980407, 50 pp., Cont.-in-part of U.S. Ser. No. 237,586, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1995-549829 19951116. PRIORITY: US 1993-80028 19930618; US 1994-237586 19940511; WO 1994-US5634 19940519.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5736539	A	19980407	US 1995-549829	19951116
WO 9500497	A1	19950105	WO 1994-US5634	19940519
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9404326	A	19951214	ZA 1994-4326	19940617

IT **169448-91-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylpiperazines and related compds. as inhibitors of farnesyl-protein transferase)
RN 169448-91-3 CAPLUS
CN Carbamic acid, [1-[[4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-1-piperazinyl]methyl]-2-[(triphenylmethyl)thio]ethyl]-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

1998:180864 Document No. 128:230251 Preparation of benzocycloheptapyridines as farnesyl protein transferase inhibitors. Taveras, Arthur G.; Mallams, Alan K.; Afonso, Adriano; Remiszewski, Stacy W.; Njoroge, F. George; Doll, Ronald J.; Lalwani, Tarik; Alvarez, Carmen (Schering Corp., USA). PCT Int. Appl. WO 9811091 A2 19980319, 147 pp. DESIGNATED STATES: W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US19976 19970911. PRIORITY: US 1996-713297 19960913; US 1997-877453 19970617.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811091	A2	19980319	WO 1997-US19976	19970911
	WO 9811091	A3	19980611		
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9851966	A1	19980402	AU 1998-51966	19970911
	EP 934303	A2	19990811	EP 1997-946875	19970911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
	CN 1237164	A	19991201	CN 1997-199597	19970911
	BR 9712980	A	20000418	BR 1997-12980	19970911
	NZ 334454	A	20000825	NZ 1997-334454	19970911
	JP 2001500515	T2	20010116	JP 1998-514032	19970911
	NO 9901235	A	19990510	NO 1999-1235	19990312
	KR 2000036110	A	20000626	KR 1999-702133	19990312

IT **204712-51-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzocycloheptapyridines as farnesyl protein transferase inhibitors)

RN 204712-51-6 CAPLUS

CN 1H-Pyrrole-1-acetic acid, 2-[[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
1999:53389 Document No. 130:139358 Preparation and formulation of tricyclic compounds useful for inhibition of farnesyl protein transferase. Taveras, Arthur G.; Mallams, Alan K.; Afonso, Adriano; Remiszewski, Stacy W.; Njoroge, F. George; Doll, Ronald; Lalwani, Tarik; Alvarez, Carmen (Schering Corporation, USA). U.S. US 5861395 A 19990119, 71 pp. (English). CODEN: USXXAM. APPLICATION: US 1997-927469 19970911.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5861395	A	19990119	US 1997-927469	19970911

IT **204712-51-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. useful for inhibition of farnesyl protein transferase)
RN 204712-51-6 CAPLUS
CN 1H-Pyrrole-1-acetic acid, 2-[[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2000:881143 Document No. 134:42075 Preparation of novel isoquinoline derivatives as If current inhibitors. Watanabe, Toshihiro; Kakefuda, Akio; Okazaki, Toshio; Masuda, Noriyuki; Wada, Koichi (Yamanouchi Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2000075133 A1 20001214, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP3564 20000601. PRIORITY: JP 1999-156217 19990603.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000075133	A1	20001214	WO 2000-JP3564	20000601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1186601	A1	20020313	EP 2000-931652	20000601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6573279	B1	20030603	US 2001-980402	20011203

IT **312752-42-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinoline derivs. as If current inhibitors)
RN 312752-42-4 CAPLUS
CN 1-Pyrrolidinepropanamide, N-1,3-benzodioxol-5-yl-2-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]-, (2S)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 312752-41-3
CMF C26 H31 N3 O6

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



L10 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2000:441625 Document No. 133:68909 Mutilin 14-ester derivatives having antibacterial activity. Brooks, Gerald; Hunt, Eric (Smithkline Beecham P.L.C., UK). PCT Int. Appl. WO 2000037074 A1 20000629, 40 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP9577 19991207. PRIORITY: GB 1998-28005 19981218.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000037074	A1	20000629	WO 1999-EP9577	19991207

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT **278797-33-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(mutilin 14-ester derivs. with antibacterial activity)
RN 278797-33-4 CAPLUS
CN 1H-Indole-1-acetic acid, 2-(1-piperidinylcarbonyl)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2001:904160 Document No. 136:20087 Preparation of 4-anilinoquinazoline derivatives for the treatment of tumors. Hennequin, Laurent Francois Andre; Ple, Patrick (Astrazeneca Ab, Swed.; Astrazeneca Uk Limited). PCT Int. Appl. WO 2001094341 A1 20011213, 234 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB2424 20010601. PRIORITY: EP 2000-401581 20000606; EP 2001-400297 20010207; EP 2001-400565 20010305.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001094341	A1	20011213	WO 2001-GB2424	20010601
	WO 2001094341	C2	20030417		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1292594	A1	20030319	EP 2001-934176	20010601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011335	A	20030610	BR 2001-11335	20010601
	BG 107332	A	20030731	BG 2002-107332	20021128
	NO 2002005792	A	20021202	NO 2002-5792	20021202

IT **379231-65-9P**, 4-(2,4-Dichloro-5-methoxyanilino)-7-(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline **379231-76-2P**, 4-(2-Bromo-5-methoxyanilino)-7-

(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline **379231-90-0P**, 4-(2,3-Methylenedioxyanilino)-7-(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinoquinazoline derivs. for treatment of tumors)

RN 379231-65-9 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2,4-dichloro-5-methoxyphenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379231-76-2 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2-bromo-5-methoxyphenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379231-90-0 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2001:78374 Document No. 134:147596 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands. Moinet, Christophe; Sackur, Carole; Thurieau, Christophe (Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.). PCT Int. Appl. WO 2001007424 A1 20010201, 428 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY,

DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (French). CODEN: PIXXD2. APPLICATION: WO 2000-FR2095 20000721. PRIORITY: FR 1999-9496 19990722.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001007424	A1	20010201	WO 2000-FR2095	20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2796643	A1	20010126	FR 1999-9496	19990722
BR 2000012647	A	20020409	BR 2000-12647	20000721
EP 1202980	A1	20020508	EP 2000-958575	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505453	T2	20030212	JP 2001-512509	20000721
NO 2002000314	A	20020306	NO 2002-314	20020121

IT **322749-40-6P 322752-99-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (arylimino)dihydrothiazoles as somatostatin receptor ligands)

RN 322749-40-6 CAPLUS
CN Isoquinoline, 2-[[2-[[4-(2-aminoethyl)phenyl]imino]-2,3-dihydro-3-(3-methoxypropyl)-4-thiazolyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 322752-99-8 CAPLUS
CN Piperidine, 1-[[2-[[4-(2-aminoethyl)phenyl]imino]-2,3-dihydro-3-(2-phenoxyethyl)-4-thiazolyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



L10 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2002:927432 Document No. 138:4470 Preparation of duocarmycin analogs as potent cytotoxins. Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li,

Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J. (Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA). PCT Int. Appl. WO 2002096910 A1 20021205, 118 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US17210 20020531. PRIORITY: US 2001-PV295342 20010531; US 2001-PV295259 20010531; US 2001-PV295196 20010601; US 2001-PV304908 20010711.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096910	A1	20021205	WO 2002-US17210	20020531
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003050331	A1	20030313	US 2002-160972	20020531
	US 2003064984	A1	20030403	US 2002-161234	20020531
	US 2003073852	A1	20030417	US 2002-161233	20020531

IT **477209-46-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of duocarmycin analogs as potent cytotoxins)

RN 477209-46-4 CAPLUS

CN Cyclopropa[c]pyrrolo[3,2-e]indole-7-carboxylic acid, 2-[[1-[2-(1,1-dimethylethoxy)-2-oxoethyl]-5-methoxy-1H-indol-2-yl]carbonyl]-1,2,4,5,8,8a-hexahydro-6-methyl-4-oxo-, methyl ester, (7bR,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

2002:539670 Document No. 137:93746 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands. Moinet, Christophe; Sackur, Carole; Thurieau, Christophe (Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.). PCT Int. Appl. WO 2002055510 A1 20020718, 465 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (French). CODEN: PIXXD2. APPLICATION: WO 2002-FR93 20020111. PRIORITY: FR 2001-396 20010112.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055510	A1	20020718	WO 2002-FR93	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2819508	A1	20020719	FR 2001-396	20010112

IT **322749-40-6P 322752-99-8P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (arylimino)dihydrothiazoles as somatostatin receptor ligands)

RN 322749-40-6 CAPLUS
CN Isoquinoline, 2-[[2-[[4-(2-aminoethyl)phenyl]imino]-2,3-dihydro-3-(3-methoxypropyl)-4-thiazolyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 322752-99-8 CAPLUS
CN Piperidine, 1-[[2-[[4-(2-aminoethyl)phenyl]imino]-2,3-dihydro-3-(2-phenoxyethyl)-4-thiazolyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



L10 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2002:157764 Document No. 136:200201 Preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease. Hennequin, Laurent Francois Andre; Ple, Patrick; Lambert, Christine Marie Paul (Astrazeneca AB, Swed.; Astrazeneca UK Limited). PCT Int. Appl. WO 2002016352 A1 20020228, 138 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB3649 20010815.
PRIORITY: EP 2000-402320 20000821; EP 2001-401006 20010419.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016352	A1	20020228	WO 2001-GB3649	20010815
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001078609	A5	20020304	AU 2001-78609	20010815
	EP 1313727	A1	20030528	EP 2001-956688	20010815
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013358	A	20030701	BR 2001-13358	20010815
	NO 2003000795	A	20030404	NO 2003-795	20030220

IT **401811-65-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease)
RN 401811-65-2 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

L10 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2002:31432 Document No. 136:102378 Preparation of thiazoles and oxazoles as antiinflammatories. Fujiwara, Norio; Fujita, Hitoshi; Antoku, Fujio; Sugasawa, Toshinari; Kawakami, Hajime (Sumitomo Pharmaceuticals Company, Limited, Japan). PCT Int. Appl. WO 2002002542 A1 20020110, 204 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2001-JP5540 20010628. PRIORITY: JP 2000-198074 20000630.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002542	A1	20020110	WO 2001-JP5540	20010628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001066345	A5	20020114	AU 2001-66345	20010628
	EP 1300401	A1	20030409	EP 2001-943850	20010628
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

IT **389147-90-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles and oxazoles as antiinflammatories)
RN 389147-90-4 CAPLUS
CN Benzamide, N-[3-[3-(acetylamino)propyl]-4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2(3H)-thiazolylidene]-2,4-dimethoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2003:527530 Document No. 139:79144 Prepn. of 5-member cyclic compounds as antiinflammatory agents. Fujiwara, Norio; Fujita, Kazushi; Yasutoku, Fujio; Kanzawa, Toshishige; Kawakami, Hajime (Sumitomo Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2003192591 A2 20030709, 72 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2001-396157 20011227.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003192591	A2	20030709	JP 2001-396157	20011227

IT **389147-90-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-member cyclic compds. as antiinflammatory agents)
RN 389147-90-4 CAPLUS
CN Benzamide, N-[3-[3-(acetylamino)propyl]-4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2(3H)-thiazolylidene]-2,4-dimethoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2003:434373 Document No. 139:6886 Preparation of quinazoline derivatives for the treatment of T cell mediated diseases. Moore, Nelly Corine; Oldham, Keith (Astrazeneca A.B., Swed.; Astrazeneca UK Limited). PCT Int. Appl. WO 2003045395 A1 20030605, 217 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-GB5222 20021120. PRIORITY: GB 2001-28108 20011123.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045395	A1	20030605	WO 2002-GB5222	20021120

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **379231-65-9P**, (S)-7-[2-(2-[[Piperidino]carbonyl]pyrrolidin-1-yl)ethoxy]-5-[[tetrahydropyran-4-yl]oxy]-4-[[2,4-dichloro-5-methoxyphenyl]amino]quinazoline **379231-76-2P**, (S)-7-[2-(2-[[Piperidino]carbonyl]pyrrolidin-1-yl)ethoxy]-5-[[tetrahydropyran-4-yl]oxy]-4-[[2-bromo-5-methoxyphenyl]amino]quinazoline **379231-90-0P**, (S)-7-[2-(2-[[Piperidino]carbonyl]pyrrolidin-1-yl)ethoxy]-5-[[tetrahydropyran-4-yl]oxy]-4-[[2,3-methylenedioxyphenyl]amino]quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazoline derivs. for treatment of T cell mediated diseases)

RN 379231-65-9 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2,4-dichloro-5-methoxyphenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379231-76-2 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2-bromo-5-methoxyphenyl)amino]-5-

[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379231-90-0 CAPLUS
CN Piperidine, 1-[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2003:434346 Document No. 139:22222 Preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases. Moore, Nelly Corine; Oldham, Keith (Astrazeneca A.B., Swed.; Astrazeneca UK Limited). PCT Int. Appl. WO 2003045364 A2 20030605, 127 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English).
CODEN: PIXXD2. APPLICATION: WO 2002-GB5217 20021120. PRIORITY: GB 2001-28109 20011123.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045364	A2	20030605	WO 2002-GB5217	20021120
	WO 2003045364	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **401811-65-2P**, (S)-6-Methoxy-7-[2-[2-piperidinocarbonylpyrrolidin-1-yl]ethoxy]-4-[[2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases)

RN 401811-65-2 CAPLUS

CN Piperidine, 1-[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 HCl

L10 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
2003:356252 Document No. 138:368891 Preparation of arylazolecarboxamides for the treatment of obesity. Coish, Philip D. G.; O'Connor, Stephen J.; Wickens, Philip; Zhang, Chengzhi; Zhang, Hai-Jun (Bayer Corporation, USA). PCT Int. Appl. WO 2003037332 A1 20030508, 253 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US32895 20021015. PRIORITY: US 2001-PV329236 20011012.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003037332	A1	20030508	WO 2002-US32895	20021015

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **521084-04-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylazolecarboxamides for the treatment of obesity)
RN 521084-04-8 CAPLUS
CN Propanoic acid, 2-[[4-[1-(2-methoxyethyl)-4-methyl-5-(1-piperidinylcarbonyl)-1H-imidazol-2-yl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



1994:270133 Document No. 120:270133 Preparation of carbostyril derivatives as blood platelet aggregation inhibitors.. Sato, Seiji; Yukawa, Hirotaka;

Kihara, Yoshito; Koga, Nobuyuki; Saito, Mashiro; Nishi, Takao (Otsuka Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9304042 A1 19930304, 218 pp. DESIGNATED STATES: W: AU, CA, KR, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1992-JP1041 19920818. PRIORITY: JP 1991-211268 19910823.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9304042	A1	19930304	WO 1992-JP1041	19920818
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	CA 2093633	AA	19930224	CA 1992-2093633	19920818
	AU 9224292	A1	19930316	AU 1992-24292	19920818
	AU 653060	B2	19940915		
	EP 569592	A1	19931118	EP 1992-917806	19920818
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 05194405	A2	19930803	JP 1992-221206	19920820
	US 5506239	A	19960409	US 1993-39301	19930422
	US 5658926	A	19970819	US 1995-541579	19951010

IT **151641-21-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)
RN 151641-21-3 CAPLUS
CN Piperidine, 1-[[1-[4-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]butyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



1995:921904 Document No. 123:339733 Preparation of indole derivatives for treatment of osteoporosis. Machii, Daisuke; Takai, Haruki; Kosaka, Nobuo; Seo, Hisakatsu; Sugiyama, Tomomi; Nakamura, Joji; Ishida, Hiroyuki; Gomi, Katsushige; Sato, Soichiro; Uchii, Masako (Japan). PCT Int. Appl. WO 9519343 A1 19950720, 48 pp. DESIGNATED STATES: W: AU, CA, CN, FI, HU, JP, KR, NO, NZ, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1995-JP19 19950111. PRIORITY: JP 1994-3334 19940118.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519343	A1	19950720	WO 1995-JP19	19950111
	W: AU, CA, CN, FI, HU, JP, KR, NO, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2181374	AA	19950720	CA 1995-2181374	19950111

AU 9514247	A1	19950801	AU 1995-14247	19950111
EP 741132	A1	19961106	EP 1995-905756	19950111
EP 741132	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 215932	E	20020415	AT 1995-905756	19950111
US 5891902	A	19990406	US 1996-676177	19960715

IT **170365-22-7P 170365-34-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. for treatment of osteoporosis)

RN 170365-22-7 CAPLUS
CN Piperidine, 1-[[3-[bis[4-(methoxymethoxy)phenyl]methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 170365-34-1 CAPLUS
CN Piperidine, 1-[[3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 170365-33-0
CMF C31 H35 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



1997:195777 Document No. 126:185982 Preparation of indole derivatives for the treatment of osteoporosis. Machii, Daisuke; Takai, Haruki; Suzuki, Koji; Kosaka, Nobuo; Sato, Soichiro (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 9703965 A1 19970206, 106 pp. DESIGNATED STATES: W: AU, CA, CN, HU, JP, KR, NO, NZ; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1996-JP1980 19960716. PRIORITY: JP 1995-181951 19950718.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9703965	A1	19970206	WO 1996-JP1980	19960716
W: AU, CA, CN, HU, JP, KR, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5891902	A	19990406	US 1996-676177	19960715
CA 2199978	AA	19970206	CA 1996-2199978	19960716
AU 9663701	A1	19970218	AU 1996-63701	19960716
EP 782989	A1	19970709	EP 1996-923101	19960716
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

IT **187533-77-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. for the treatment of osteoporosis)

RN 187533-77-3 CAPLUS

CN Piperidine, 1-[[1-[2-(dimethylamino)ethyl]-3-(diphenylmethyl)-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)